Jazz Pharmaceuticals (JAZZ) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 61.5% versus a loss of 26.4%. Over five years, SMMT leads with a +233.4% price change compared with +58.1% for JAZZ. Jazz Pharmaceuticals is the larger company by market cap ($14.22 billion vs $13.75 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JAZZ | SMMT |
|---|---|---|
| Share price | $219.11 | $17.24 |
| Market cap | $14.22B | $13.75B |
| 1-day change | -1.50% | +0.41% |
| YTD return | +30.85% | -1.83% |
| 1-year return | +61.45% | -26.44% |
| 5-year return | +58.10% | +233.40% |
| P/E ratio (TTM) | 15.02 | — |
| Forward P/E | 8.49 | — |
| EPS (TTM) | $14.59 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.27B | — |
| Revenue growth (YoY) | +4.88% | — |
| Net income (latest FY) | $-356.15M | $-1.08B |
| Operating margin | -10.08% | — |
| Net margin | -8.35% | — |
| 52-week high | $266.38 | $29.23 |
| 52-week low | $128.80 | $12.07 |
| Distance from 52-week high | -17.75% | -41.02% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +34.41% | +72.56% |
| Average volume | 859.22K | 5.82M |
| Shares outstanding | 64.91M | 797.75M |
| Employees | 2,890 | 265 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed SMMT by 87.9 percentage points over the past year.
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
JAZZ vs SMMT FAQ
Which is bigger, Jazz Pharmaceuticals or Summit Therapeutics?
Jazz Pharmaceuticals (JAZZ) is larger, with a market capitalization of $14.22B compared with $13.75B for Summit Therapeutics (SMMT).
Which stock has performed better over the past year, JAZZ or SMMT?
JAZZ returned +61.45% over the past 12 months, compared with -26.44% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Jazz Pharmaceuticals and Summit Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.